Aspirin, NOACs, warfarin: which is the best choice to tackle cognitive decline in elderly patients? Insights from the GIRAF and ASCEND-Dementia trials presented at the AHA 2021

Pasquale Mone, Bruno Trimarco, Gaetano Santulli

Research output: Contribution to journalComment/debatepeer-review

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)E7-E8
JournalEuropean Heart Journal - Cardiovascular Pharmacotherapy
Issue number3
StatePublished - May 1 2022


  • Aspirin
  • Cognitive Impairment
  • Dabigatran
  • Elderly
  • NOAC
  • Older Adults
  • VKA
  • Warfarin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this